Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.4791
Dollar change
-0.0046
Percentage change
-0.95
%
Index- P/E- EPS (ttm)-0.28 Insider Own22.83% Shs Outstand18.33M Perf Week44.44%
Market Cap9.23M Forward P/E- EPS next Y-0.28 Insider Trans0.00% Shs Float14.86M Perf Month26.11%
Income-5.30M PEG- EPS next Q-0.04 Inst Own4.47% Short Float1.15% Perf Quarter-19.90%
Sales0.00M P/S- EPS this Y39.29% Inst Trans154.01% Short Ratio0.44 Perf Half Y-47.92%
Book/sh0.21 P/B2.31 EPS next Y-64.71% ROA-84.50% Short Interest0.17M Perf Year22.72%
Cash/sh0.17 P/C2.78 EPS next 5Y- ROE-95.14% 52W Range0.28 - 2.42 Perf YTD-16.68%
Dividend Est.- P/FCF- EPS past 5Y-2.02% ROI-139.12% 52W High-80.20% Beta1.88
Dividend TTM- Quick Ratio11.62 Sales past 5Y0.00% Gross Margin- 52W Low71.72% ATR (14)0.08
Dividend Ex-Date- Current Ratio11.62 EPS Y/Y TTM78.35% Oper. Margin0.00% RSI (14)61.44 Volatility42.64% 19.89%
Employees4 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price0.40
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q48.61% Payout- Rel Volume1.07 Prev Close0.48
Sales Surprise- EPS Surprise14.29% Sales Q/Q- EarningsFeb 29 BMO Avg Volume385.58K Price0.48
SMA2030.93% SMA5016.93% SMA200-46.73% Trades Volume414,208 Change-0.95%
Mar-26-24 09:15AM
Feb-29-24 09:15AM
Feb-28-24 09:15AM
Jan-22-24 09:00AM
Jan-02-24 07:05AM
09:55AM Loading…
Nov-14-23 09:55AM
Nov-13-23 07:05AM
Nov-06-23 07:05AM
Oct-12-23 07:05AM
Sep-18-23 07:05AM
Sep-12-23 07:05AM
Aug-15-23 07:48AM
Aug-14-23 07:05AM
Aug-12-23 09:40AM
Aug-10-23 07:05AM
07:05AM Loading…
Aug-09-23 07:05AM
Aug-03-23 04:05PM
Jul-24-23 08:40AM
Jul-17-23 02:20PM
07:05AM
May-25-23 04:05PM
May-16-23 10:26AM
May-15-23 07:05AM
May-11-23 07:49AM
07:39AM
07:05AM
May-04-23 07:05AM
Apr-25-23 01:07PM
Apr-24-23 04:15PM
Mar-16-23 07:10AM
07:05AM Loading…
Mar-14-23 07:05AM
Mar-07-23 07:05AM
Feb-13-23 07:05AM
Jan-05-23 07:00AM
Dec-05-22 08:30AM
Nov-29-22 07:05AM
Nov-22-22 06:15AM
Nov-14-22 07:05AM
Nov-03-22 07:05AM
Sep-23-22 07:27AM
Sep-22-22 04:15PM
Sep-19-22 10:04PM
04:05PM
11:20AM
09:33AM
08:22AM
07:05AM
Sep-16-22 09:30AM
Sep-12-22 09:30AM
Sep-05-22 06:47AM
Aug-15-22 07:24AM
07:05AM
Aug-11-22 07:05AM
Aug-10-22 04:01PM
Aug-08-22 08:30AM
Aug-04-22 07:05AM
Jul-26-22 08:30AM
Jul-19-22 08:30AM
Jun-01-22 07:05AM
May-17-22 12:05PM
May-12-22 07:05AM
May-05-22 07:05AM
Apr-28-22 07:05AM
Mar-28-22 07:10PM
Mar-21-22 06:25AM
Mar-17-22 07:05AM
Mar-10-22 07:05AM
Mar-08-22 04:05PM
Feb-28-22 07:05AM
Feb-01-22 03:00AM
Jan-26-22 04:30PM
Jan-04-22 04:05PM
Dec-01-21 07:05AM
Nov-15-21 07:34AM
Nov-11-21 07:05AM
Nov-04-21 07:05AM
Sep-28-21 03:33PM
Sep-08-21 07:05AM
Sep-02-21 07:05AM
Aug-19-21 07:05AM
Aug-16-21 08:30AM
07:45AM
07:05AM
Aug-12-21 07:05AM
Aug-11-21 07:05AM
Aug-09-21 07:05AM
Aug-05-21 07:05AM
Jul-26-21 07:05AM
Jul-08-21 11:44AM
Jun-21-21 07:13AM
Jun-15-21 06:41AM
Jun-09-21 08:40AM
07:05AM
Jun-04-21 07:05AM
Jun-03-21 05:43AM
Jun-02-21 07:05AM
May-24-21 07:05AM
May-18-21 07:31AM
May-13-21 07:05AM
06:30AM
Virios Therapeutics, Inc. engages in pharmaceutical products for fibromyalgia and other related conditions. The firm engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1, a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pridgen WilliamDirectorAug 21 '23Buy1.3015,33519,99252,045Aug 22 03:57 PM
Duncan Gregory ScottCHIEF EXECUTIVE OFFICERAug 17 '23Buy1.2525,00031,24557,461Aug 18 07:05 AM